Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Abroad (travel likely)RecruitingPHASE1
Conditions
CLL/SLL · Waldenstrom Macroglobulinemia · Follicular Lymphoma · Diffuse Large B Cell Lymphoma · Mantle Cell Lymphoma · Marginal Zone Lymphoma · Hairy Cell Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Duke Univerisity, Durham, North Carolina, United States
University of Cincinnati, Cincinnati, Ohio, United States
Ohio State University, Columbus, Ohio, United States
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States